All Articles

The opioid treatment specialist projects over $1.1B in revenue, driven by its flagship drug SUBLOCADE and a major strategic overhaul in the U.S.

A new vectorized antibody therapy for ALS, VTx-002, has been granted FDA Fast Track status, accelerating its path to patients battling the disease.

With an expanded Boehringer Ingelheim deal and a new CMO, Enara Bio is set to take its novel 'Dark Antigen' therapy into human trials in 2026.

The medtech firm's preliminary results show a Q4 revenue uptick but miss yearly estimates, signaling a stabilizing but cautious path forward for 2026.

Otis secures a major TfL contract to upgrade 172 escalators, blending a century of history with future-ready tech for a smarter, more reliable commute.

A looming 10-million-ton copper deficit threatens to derail the AI revolution and the green energy transition, sparking a new era of geopolitical competition.

Replicate Bioscience secures major funding to develop next-gen self-replicating RNA vaccines, aiming for more durable and accessible global health solutions.

With gold hitting record highs, investors are keenly awaiting Kinross's update on three critical US projects that could define its production for a decade.

Cybersecurity firm Corero appoints an award-winning leader to supercharge its partner program, signaling a major push in the competitive DDoS defense market.

The special mission aviation provider completes a buyout of Bain Capital, consolidating NTC Group's ownership and securing new capital to expand its services.

With a 432% share price jump and billions in financing lined up, Troilus Gold's Quebec project is becoming a cornerstone of North America's critical minerals.

Calgary-based Horizon Petroleum faces a Management Cease Trade Order over delayed financial filings, raising questions about its European operations.

AI data platform Protege raises its Series A to $65M, tackling the critical data bottleneck with an ethical, licensing-first model for real-world data.

Eurythmics legend Dave Stewart launches a new venture builder to give artists control over their IP and revenue. But can this "creativity-first" model work?

EF Adventures' new Tour de France tours let fans ride race routes and party with pros, setting a new standard for immersive sports tourism.

Rani Therapeutics starts Phase 1 trials for an oral obesity drug, challenging the injectable market with a novel delivery system and a dual-action compound.

Challenger brand Kodiak partners with analytics giant NIQ, signaling a new data-driven era for competition in the crowded CPG breakfast and snacking aisles.

With major backing from Goldman Sachs, a biotech firm is advancing a potentially life-changing gene therapy for a rare, progressive form of blindness.

Luxury brand owner Tapestry partners with Pivot Energy on Illinois solar projects, powering homes and funding new green job training programs for locals.

Westwater Resources heads to a key investor conference, carrying the weight of its Alabama graphite projects and the future of America's EV supply chain.